Connect with us

News

Women As One Award winner leads the charge in VESALIUS-CV results

Published

on

By Women As One

When the VESALIUS-CV trial was conceived in 2018, it began a multi-year effort to answer a critical question in preventive cardiology.

Could evolocumab, marketed as Repatha, a human monoclonal antibody that inhibits PCSK9, reduce major cardiovascular events in patients at high risk but without a prior myocardial infarction or stroke?

The scientific stakes were high. For one of its leaders, Dr Erin Bohula, the journey was also deeply meaningful.

Dr Bohula is a cardiologist at Brigham and Women’s Hospital in Boston and an assistant professor at Harvard Medical School.

She joined the trial early in its development and ultimately became a co-principal investigator.

“I started as an investigator and moved up to become co-PI,” she shared in an exclusive Women As One interview at AHA 2025, shortly after presenting the trial’s findings during the Late-Breaking Science session.

“It has been a journey of growth, and to now be part of something that will change practice is incredibly exciting.”

The science and the stage

VESALIUS-CV, supported by Amgen, is one of the largest primary-prevention studies of a PCSK9 inhibitor conducted to date.

The trial enrolled patients with significant cardiovascular risk profiles, including extensive atherosclerotic burden or high-risk comorbidities, but no prior major atherosclerotic event.

Its design sought to determine whether achieving very low LDL levels with evolocumab could meaningfully reduce cardiovascular outcomes long before the first heart attack or stroke occurs.

The trial results delivered an important message.

Earlier and more intensive lipid lowering has the potential to shift the trajectory of disease, not only in those recovering from events but in those who have never had one.

Its scientific impact is matched by the significance of its leadership.

Having a woman guiding a trial of this scale reinforces a growing truth within cardiovascular research.

Women are not only participants in clinical studies. They are shaping the scientific agenda.

As Dr Bohula described the experience of preparing for AHA 2025, her emotion was evident.

“We are very happy that everyone’s effort has paid off to deliver a strong result. What is most rewarding is knowing this data will help patients.”

Why representation in leadership matters

The success of VESALIUS-CV contributes to a larger cultural and clinical reality. Leadership diversity strengthens clinical research.

“Historically, women have been underrepresented in both cardiology and clinical trials,” she noted.

“I truly believe one way to change that is to ensure the leadership team reflects the populations we want to enroll.”

Diverse leadership improves trust, broadens recruitment, and ensures study findings are more generalizable.

“When women see women leading trials, they are more likely to see themselves participating.

“Representation opens doors.”

Mentorship as a catalyst

When asked what advice she would offer early-career women in cardiology, Dr Bohula did not hesitate. Mentorship.

“That has really been the key for me. I have had mentors who appreciated my value and gave me platforms to grow. That is what made the difference.”

She emphasised the importance of both formal mentorship programs and informal supporters who advocate for women behind the scenes.

“Find the people who believe in you. That is what gets you from the back of the room to the podium.”

The role of industry and advocacy

Organisations such as Women As One and intentional efforts from industry sponsors are helping shift the landscape for women in cardiovascular research.

“Women As One gave me an award years ago, and with it came support to attend a major meeting. That one opportunity connected me with people in the field and gave me the chance to be seen and heard.”

She added that industry sponsors have meaningful influence over who receives leadership opportunities.

“Industry has a huge opportunity to be intentional about who they invite into leadership roles, who sits on advisory boards, and who they elevate.

“And I have seen that change happening.”

Why this work matters

VESALIUS-CV is a milestone in preventive cardiology.

It demonstrates the long-term benefits of aggressive LDL lowering in high-risk individuals before events occur.

It also underscores that who leads the science matters just as much as the data itself.

At Women As One, we remain committed to ensuring that more women across all stages of their careers have the mentorship, opportunities, and visibility they need to shape the future of cardiovascular research.

When women lead, the entire field moves forward.

Learn more about Women As One at womenasone.org

Hormonal health

Hormone therapy users report healthier lifestyles

Published

on

Menopausal women using hormone therapy reported healthier diet, exercise and sleep habits than non-users in a study of more than 10,000 women.

The menopause transition is associated with a higher risk of chronic health conditions and symptoms including hot flushes and problems affecting the urinary and genital systems.

Hormone therapy is often used to manage these symptoms, but it remains unclear whether it affects health outcomes directly or indirectly through changes in health behaviours.

Previous research has produced mixed results, with some studies suggesting that postmenopausal women pay greater attention to maintaining a healthy lifestyle.

 

The cross-sectional analysis examined whether menopause status and hormone therapy use were linked to diet, physical activity and sleep duration.

A cross-sectional study assesses participants at one point in time. It can identify associations but cannot establish whether one factor directly caused another.

Diet, exercise and sleep are described as modifiable health behaviours because people may be able to change them to improve their health.

The researchers found that postmenopausal women who had never used hormone therapy reported eating less fruit and vegetables.

Women who had never used the treatment were also 19 per cent less likely to meet guidelines for muscle-strengthening activity.

Sleep duration was shorter among postmenopausal women who had never used hormone therapy.

Compared with premenopausal and perimenopausal women, the likelihood of meeting sleep guidelines was 14 per cent lower among never-users, 26 per cent lower among current users and 24 per cent lower among past users.

Perimenopause is the transitional period before menopause, when hormone levels and menstrual periods can change.

Researchers said these findings may be linked to higher levels of follicle-stimulating hormone among postmenopausal women who do not use hormone therapy.

They may also relate to lower levels of oestradiol, a form of oestrogen, which have previously been associated with poorer sleep.

Hot flushes and urogenital symptoms can also disrupt sleep, although hormone therapy may ease these symptoms.

Dr Stephanie Faubion, medical director for The Menopause Society, said: “This large observational study underscores that women who use hormone therapy tend to adopt overall healthier lifestyles.

“Although this association may partly reflect better symptom control enabling healthier behaviours, healthy-user bias is likely a significant contributor.

“Women who choose to use hormone therapy are often more proactive in their healthcare and may systematically differ from nonusers in socioeconomic resources, access to care, and health literacy.

“This largely explains why early observational studies of hormone therapy suggested cardiovascular benefits that were not confirmed in subsequent randomised, controlled trials.”

Continue Reading

Ageing

Strength training may lower heart disease risk in women, study suggests

Published

on

Women who do strength training may have a lower risk of major cardiovascular disease, particularly alongside aerobic activity, a study suggests.

Cardiovascular disease is the leading cause of death worldwide. Aerobic activities such as brisk walking, jogging, cycling and swimming are already established ways to help reduce the risk.

Strength or resistance training, also known as RT, is less established as a prevention strategy. It makes muscles work against a force and can involve body weight, free weights, resistance bands or machines.

Current US guidelines recommend at least two days of strength training and 150 minutes of moderate-to-vigorous aerobic activity each week.

They also recommend limiting sedentary behaviour, including prolonged television viewing, which is considered an independent risk factor for cardiovascular disease.

Dr Tianyue Zhang, lead study author and scientist in the department of nutrition at the Harvard T.H. Chan School of Public Health, said: “Despite its established health benefits, RT is often overlooked as a prevention strategy for CVD, and its impact on CVD risk, especially in middle-aged and older women, remains understudied.

“A key question is, how much does it add beyond aerobic activity alone?”

Researchers analysed data from 117,025 women participating in the Nurses’ Health Study and Nurses’ Health Study II.

The two groups had average starting ages of 66.8 and 48.1 years respectively.

The women reported their resistance training every four years, with exercises involving the arms and legs recorded separately.

Time spent watching television was used as the main measure of sedentary behaviour.

The researchers examined exercise and television-viewing habits alongside the incidence of major cardiovascular disease.

Major cardiovascular events included fatal or non-fatal heart attacks, strokes, coronary artery bypass surgery and percutaneous coronary intervention.

Coronary artery bypass surgery redirects blood around narrowed or blocked heart arteries. Percutaneous coronary intervention uses a small balloon, often followed by a stent, to open a narrowed artery.

Higher levels of strength training were associated with a lower risk of major cardiovascular disease, particularly heart attacks.

No statistically significant link with stroke was found when resistance exercise was considered separately.

Women completing at least two hours of strength training a week had a 20 per cent lower risk of major cardiovascular disease and a 44 per cent lower risk of heart attack than those doing none.

Each additional hour a week was associated with a five per cent lower risk of major cardiovascular disease and a 14 per cent lower risk of heart attack.

The associations weakened somewhat after researchers accounted for body mass index and conditions including diabetes, high blood pressure and high cholesterol, but remained clear.

Body mass index, or BMI, compares weight with height and is commonly used to assess whether someone is within a healthy weight range.

Strength training was also linked to additional benefits among women who did aerobic activity.

Women completing at least two hours of strength training and 150 minutes of aerobic activity each week had a 45 per cent lower risk of heart attack than those reporting no physical activity.

Women who met recommendations for strength training, aerobic activity and reduced television viewing had the lowest risks of major cardiovascular disease, heart attack and stroke compared with those who met some or none of the recommendations.

Zhang said: “These findings suggest that, within an already active population, RT is associated with additional reductions in CVD risk above and beyond overall aerobic activity.

“Alongside aerobic activity and reductions in sedentary behaviour, RT may be an important component of public health strategies for cardiovascular prevention in women.”

The study relied on participants reporting their own resistance training, meaning the data may not always have been precise.

Researchers also noted the possible influence of unmeasured factors and the limited diversity of participants.

They were unable to fully separate the effects of the type of resistance training performed from the overall amount completed.

Dr Harlan M. Krumholz, professor at Yale School of Medicine, said: “We have long encouraged resistance training, and this study provides strong evidence to reinforce that message.

“It should be included in a well-rounded health routine to support function and longevity.”

Continue Reading

Pregnancy

Women with pre-eclampsia at increased risk of chronic kidney disease, study finds

Published

on

Women who develop pre-eclampsia face a higher risk of chronic kidney disease and high blood pressure later in life, new research suggests.

The amount of protein found in the urine during pregnancy may help identify those at greatest risk of developing long-term health problems.

Pre-eclampsia usually involves high blood pressure and increased protein in the urine. Some women also experience severe headaches and changes to their vision.

The condition cannot be treated during pregnancy and, in some cases, labour must be induced early to protect both the woman and baby.

The study found that the condition may be linked to longer-term health problems.

Anne Høy Seemann Vestergaard, a medical doctor and PhD at the department of clinical medicine at Aarhus University, said: “What we can see is a clear association between pre-eclampsia and the development of high blood pressure, chronic kidney disease and cardiovascular disease later in life.”

The researchers found that the amount of protein passed in the urine during pregnancy was linked to the risk of developing chronic conditions after giving birth.

Protein in the urine can indicate that the kidneys are not filtering blood normally.

Vestergaard said: “The most surprising finding was how clearly the amount of protein in the urine during pre-eclampsia was linked to the risk of later high blood pressure and chronic kidney disease. Women with moderate to severe protein excretion had a higher risk of both conditions compared with women with low or no protein excretion.”

Among women with pre-eclampsia and moderate to severe levels of protein in the urine, around one in 20 developed chronic kidney disease within 10 years and around one in six developed high blood pressure.

Most women in the study did not develop long-term complications, but the researchers said the increased risk should still be taken seriously because the potential effects can be severe.

Vestergaard said: “At first glance, this may sound like a low number, but it represents a markedly increased risk when the groups are compared. In the group with pre-eclampsia and high levels of protein in the urine, around 1 in 20 women developed chronic kidney disease within ten years, including early stages of the disease, compared with around 1 in 100 in the group with lower or no protein excretion.”

She added: “That is a considerable number in light of the fact that chronic kidney disease is a potentially serious condition that can progress to kidney failure if isn’t diagnosed early.”

The findings suggest women who experience pre-eclampsia may benefit from more systematic monitoring after pregnancy.

Vestergaard said: “Our study suggests that these women may benefit from monitoring of blood pressure and kidney function after pregnancy.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.